Cholesterol

Both statins and newer non-statin medications are important in combination to effectively lower atherogenic lipid levels and reduce cardiovascular risk.

Muvalaplin inhibits the formation of Lp(a) by blocking the initial interaction between apolipoprotein(a) and apo(b).

Lipoprotein(a) is a known risk factor for atherosclerotic cardiovascular disease.

Familial chylomicronemia syndrome (FCS) currently has no FDA-approved treatment and is associated with an increased risk of acute pancreatitis.

Twice-yearly dosing could significantly improve adherence rates.

Improving collaboration and communication between all members of the health care team is one way to address these challenges.

High fluctuations (in the top 25%) in total cholesterol were associated with a 60% increase in dementia and a 23% increase in cognitive decline.

Lerodalcibep is a novel, third-generation, anti-PCSK9 therapy small binding protein.

Bisphenol A (BPA) is a chemical compound that is linked to various adverse health effects.

New recommendations from the American Stroke Association (ASA) emphasize the importance of healthy lifestyle habits and addressing health equity to reduce stroke risk.

The researchers observe that the combination treatment results in higher serum levels compared with ezetimibe alone.

Zodasiran is an RNA interference therapy targeting the ANGPTL3 loss-of-function mutation.

High cholesterol levels are known risk factors for atherosclerotic cardiovascular disease.

Cholesin, a hormone found in the gut, may enhance the cholesterol-lowering capabilities of statins.

Erin McConnell, PharmD, discuss the clinical decision-making process for choosing between statins, PSCK9 inhibitors, or newer agents like inclisiran.

Erin McConnell, PharmD, discusses the importance of effective cholesterol management for preventing heart disease.

Exposure to high cholesterol levels is a significant risk factor for atherosclerosis cardiovascular disease.

FCS is a severe, rare genetic disease in which patients have extremely high triglyceride levels, typically above 880 mg/dL.

Alirocumab (Praluent; Regeneron), is a PCSK9 inhibitor indicated for the treatment of adults with heterozygous familiar hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease.

Pharmacists can enhance ASCVD management by supporting patient adherence through the administration and monitoring of inclisiran.

Pharmacists play an essential role in ensuring the medication is dispensed to patients with high atherosclerotic cardiovascular disease risk.

Pharmacists can play a crucial role in educating patients on the proper storage and administration of evolocumab.

Pharmacists can be essential sources of education for patients, offering them guidance on safe use and proper dosage.

Pharmacists are key resource points to navigate the nuances of keto diets and chronic health management.

Statins and non-statin cholesterol-lowering agents show potential in reducing the risk of liver cancer.